Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study

NCT04835324 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 650

Last updated 2022-03-11

No results posted yet for this study

Summary

This is a multi-center, retrospective, real-world study. The purpose of this study is to observe the effectiveness and safety of regorafenib in Chinese advanced colorectal cancer patients.

The main observational goals include overall survival(OS), 6 month OS rate, 1 year OS rate, and treatment time failure (TTF), other study goals include objective response rate( ORR)、Disease control rate(DCR)and adverse event(AE) of regorafenib.

Conditions

  • Advanced Colorectal Cancer

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV
  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER
  • The Affiliated Hospital of Qingdao University

    collaborator OTHER
  • Shanxi Province Cancer Hospital

    collaborator OTHER
  • Affiliated Hospital of Hebei University

    collaborator OTHER
  • Shandong Cancer Hospital and Institute

    collaborator OTHER
  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER
  • Hebei Medical University Fourth Hospital

    collaborator OTHER
  • First Hospital of China Medical University

    collaborator OTHER
  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Yunbo Zhao · Beijing Hospital

  • Liangjun Zhu · Jiangsu Cancer Institute & Hospital

  • Zimin Liu · The Affiliated Hospital of Qingdao University

  • Wei Bai · Shaanxi Provincial Cancer Hospital

  • Aimin Zang · Affiliated Hospital of Hebei University

  • Bo Liu · Shandong Cancer Hospital and Institute

  • Hong Zong · The First Affiliated Hospital of Zhengzhou University

  • Shengmian Li · The fourth hospital of Hebei medical university and hebei cancer hospital

  • Xiujuan Qu · First Hospital of China Medical University

  • Aiping Zhou · Cancer Hospital Chinese Academy of Medical Science

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-02-01
Completion
2022-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04835324 on ClinicalTrials.gov